Exclusives

An article, “A review of the proposed draft CAMPs LCDs compared to evidence-based medicine: a letter to the MACs for consideration,” considers Medicare RWE data in the number of CAMP applications, medical necessity, and treatment of non-DFUs...

A 272-patient RCT will examine the efficacy of multiple human placental-based skin substitutes and SoC vs SoC alone for treatment of DFUs with primary outcome of percentage of wounds with complete closure at 12 weeks. Not yet recruiting; the...

MIMOSA, a Canadian diagnostics company, announced the successful closing of its latest round of financing, which was intended to fuel the company’s ongoing commercial expansion and organizational growth.

SolasCure has been chosen for Innovate UK’s Global Incubator Program. This 6-month program, which is fully funded and delivered in partnership with the Texas Medical Centre, focuses on commercializing innovative solutions for unmet healthcare...

A 150-patient multi-center RCT will examine the effect of Derm-Maxx ADM on the healing rate of chronic DFUs unresponsive to SoC with primary outcome of the rate of wound closure at 12 weeks. The estimated study completion is Sept 2025....

A nationwide study of factors predicting burn readmissions (2016-2018) in 41,500 older adult patients found the 90-day readmission rate was 25.6% with 96.5% unplanned. An increased hospital frailty risk and lower-body-only burns were leading...

Results of a 128-patient RCT that evaluated the effectiveness of a dehydrated Amnion Chorion Membrane (dACM) for treatment of DFUs showed that dACM increased frequency, decreased median time and improved probability of complete wound closure...

A 2,270-patient multicenter observational trial evaluating the short-term clinical impact of UrgoClean Ag on the wound healing process was published. The study demonstrates a reduction in wound size and exudate level across a range of wound...

An 85-patient 2-part RCT will examine the efficacy of Dermacyte amniotic wound care matrix for the treatment of DFUs vs SoC with primary outcome of wound closure at 12 weeks. Not yet recruiting; the estimated study completion is May 2025....